AC Immune
A clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases.
The Swiss-based biopharmaceutical company designs, discovers and develops therapeutic and diagnostic products to prevent and modify diseases caused by misfolding proteins.
Diseases it is targeting with these products include Alzheimer's, Parkinson’s, Down syndrome and glaucoma.
Latest AC Immune News & Features
22 January 2024
1 December 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze